Legend Biotech (LEGN) EPS (Weighted Average and Diluted) (2019 - 2025)
Legend Biotech (LEGN) posted EPS (Weighted Average and Diluted) of $3086.4 for Q4 2025, up 105.78% on a QoQ basis from -$53412.5 in Q3 2025, and down 97.49% year-over-year from $122916.7 in Q4 2024.
Legend Biotech (LEGN) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at $3086.4 in Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) fell 97.49% year-over-year to $3086.4; the TTM figure through Dec 2025 stood at $3086.4 (down 97.49% YoY), while the FY2025 annual figure was $40864.2, up 8513474.49% from the prior year.
- EPS (Weighted Average and Diluted) advanced to $3086.4 in Q4 2025, from -$53412.5 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $122916.7 in Q4 2024 and bottomed at -$948228.6 in Q2 2024.
- A 4-year average of -$118161.4 and a median of -$0.34 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
- The widest YoY moves for EPS (Weighted Average and Diluted): up 78.87% in 2025, down 97.49% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then jumped by 65.28% to -$0.1 in 2022, then jumped by 117514598.01% to $122916.7 in 2024, then slumped by 97.49% to $3086.4 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at $3086.4 (Q4 2025), -$53412.5 (Q3 2025), and -$200348.4 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,086.42 |
| Sep 30, 2025 | -53,412.50 |
| Jun 30, 2025 | -200,348.39 |
| Dec 31, 2024 | 122,916.67 |
| Sep 30, 2024 | -223,787.50 |
| Jun 30, 2024 | -948,228.57 |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -0.30 |
| Sep 30, 2021 | -0.43 |
| Jun 30, 2021 | -0.33 |
| Mar 31, 2021 | -0.34 |
| Dec 31, 2020 | -0.22 |
| Sep 30, 2020 | -0.25 |
| Jun 30, 2020 | -0.63 |
| Mar 31, 2020 | -0.22 |
| Dec 31, 2019 | -0.32 |
| Sep 30, 2019 | -0.14 |
| Jun 30, 2019 | -0.14 |